期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到19篇文章
< 1 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Imaging alpha-synuclein pathology in Parkinson's disease 认领 引用 被引量：2
1
作者 Ruiqing Ni 《Neural Regeneration Research》 SCIE CAS CSCD 2026年第4期1566-1567,共2页
Parkinson's disease(PD)is the second most common neurodegenerative disorder.The clinical manifestations of PD include motor symptoms,such as bradykinesia,resting tremor,rigidity,and nonmotor symptoms,which include... Parkinson's disease(PD)is the second most common neurodegenerative disorder.The clinical manifestations of PD include motor symptoms,such as bradykinesia,resting tremor,rigidity,and nonmotor symptoms,which include disturbances in sleep,gastrointestinal function,and olfaction.PD misdiagnosis rates have been reported to reach approximately 30%,partly owing to the heterogeneity of parkinsonism with non-PD pathologies,and the differential diagnosis of PD from neurodegenerative diseases such as multiple systemic atrophy(MSA)and progressive supranuclear palsy poses another unmet need. 展开更多
关键词 neurodegenerative diseases neurodegenerative disorder alpha synuclein pathology parkinsons disease pd Parkinsons disease resting tremor neurodegenerative disorderthe bradykinesia
暂未订购 下载PDF
Objective assessment of bradykinesia in Parkinson’s disease using evolutionary algorithms:clinical validation 认领 引用 被引量：4
2
作者 Chao Gao Stephen Smith +10 位作者 Michael Lones Stuart Jamieson Jane Alty Jeremy Cosgrove Pingchen Zhang Jin Liu Yimeng Chen Juanjuan Du Shishuang Cui Haiyan Zhou Shengdi Chen 《Translational Neurodegeneration》 SCIE 2018年第1期167-174,共8页
Background:There is an urgent need for developing objective,effective and convenient measurements to help clinicians accurately identify bradykinesia.The purpose of this study is to evaluate the accuracy of an objecti... Background:There is an urgent need for developing objective,effective and convenient measurements to help clinicians accurately identify bradykinesia.The purpose of this study is to evaluate the accuracy of an objective approach assessing bradykinesia in finger tapping(FT)that uses evolutionary algorithms(EAs)and explore whether it can be used to identify early stage Parkinson’s disease(PD).Methods:One hundred and seven PD,41 essential tremor(ET)patients and 49 normal controls(NC)were recruited.Participants performed a standard FT task with two electromagnetic tracking sensors attached to the thumb and index finger.Readings from the sensors were transmitted to a tablet computer and subsequently analyzed by using EAs.The output from the device(referred to as"PD-Monitor")scaled from−1 to+1(where higher scores indicate greater severity of bradykinesia).Meanwhile,the bradykinesia was rated clinically using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale(MDS-UPDRS)FT item.Results:With an increasing MDS-UPDRS FT score,the PD-Monitor score from the same hand side increased correspondingly.PD-Monitor score correlated well with MDS-UPDRS FT score(right side:r=0.819,P=0.000;left side:r=0.783,P=0.000).Moreover,PD-Monitor scores in 97 PD patients with MDS-UPDRS FT bradykinesia and each PD subgroup(FT bradykinesia scored from 1 to 3)were all higher than that in NC.Receiver operating characteristic(ROC)curves revealed that PD-Monitor FT scores could detect different severity of bradykinesia with high accuracy(≥89.7%)in the right dominant hand.Furthermore,PD-Monitor scores could discriminate early stage PD from NC,with area under the ROC curve greater than or equal to 0.899.Additionally,ET without bradykinesia could be differentiated from PD by PD-Monitor scores.A positive correlation of PD-Monitor scores with modified Hoehn and Yahr stage was found in the left hand sides.Conclusions:Our study demonstrated that a simple to use device employing classifiers derived from EAs could not only be used to accurately measure different severity of bradykinesia in PD,but also had the potential to differentiate early stage PD from normality. 展开更多
关键词 Parkinson’s disease Bradykinesia Evolutionary algorithms Objective assessment Clinical validation
暂未订购 下载PDF
SARS-CoV-2感染相关炎症指标与帕金森病运动症状加重的相关性分析 认领 引用
3
作者 王乐淼 慈春玲 +3 位作者 王佳炜 吴大任 王训 程楠 《江苏大学学报（医学版）》 CAS 2026年第3期197-201,共5页
目的:探究帕金森病(Parkinson′s disease,PD)患者在感染严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)后外周血炎症指标的变化,并分析其与不同运动症状加重的相关性。方法:选择2022... 目的:探究帕金森病(Parkinson′s disease,PD)患者在感染严重急性呼吸系统综合征冠状病毒2型(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)后外周血炎症指标的变化,并分析其与不同运动症状加重的相关性。方法:选择2022年11月至2023年5月安徽中医药大学神经病学研究所附属医院收治的合并SARS-CoV-2感染的PD患者43例,采用统一帕金森病评定量表Ⅲ(Unified Parkinson′s Disease Rating Scale-Ⅲ,UPDRS-Ⅲ)分别于SARS-CoV-2感染前(未感染入院前1个月内)和感染后(确诊后7 d内)评估运动症状并进行比较;收集患者的外周血炎症指标,包括中性粒细胞计数(neutrophil count,NEUT)、淋巴细胞计数(lymphocyte count,LYM)、中性粒细胞与淋巴细胞比率(neutrophil-to-lymphocyte ratio,NLR)、C反应蛋白(C-reactive protein,CRP)、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)和IL-6,分析其与加重的运动症状的相关性,并进行Logistic回归分析筛选影响感染SARS-CoV-2后PD患者运动症状加重的独立危险因素。结果:与感染前UPDRS-Ⅲ得分[15.00(11.00,22.00)分]相比,PD患者感染后UPDRS-Ⅲ得分[(27.74±8.08)分]明显升高(Z=-5.716,P<0.05)。相关性分析结果显示,NEUT、NLR、CRP及IL-6与PD患者运动症状加重呈正相关(r值分别为0.463、0.556、0.505、0.453,P均<0.05)。Logistic回归分析结果显示,NEUT、NLR、CRP和IL-6是肌僵直加重的独立危险因素(OR=1.289、1.340、1.025、1.061,P均<0.05);NEUT、CRP和IL-6与震颤加重相关(OR=1.204、1.027、1.051,P均<0.05);CRP与姿势反射障碍风险相关(OR=1.030,P=0.019)。结论:PD患者合并SARS-CoV-2感染后运动症状显著加重,NEUT、CRP和IL-6等升高与肌僵直、震颤加重密切相关。 展开更多
关键词 帕金森病 炎性反应 运动症状 C反应蛋白 IL-6 动作迟缓 肌僵直
暂未订购 下载PDF
Role of the globus pallidus in motor and non-motor symptoms of Parkinson's disease 认领 引用 被引量：4
4
作者 Yimiao Jiang Zengxin Qi +9 位作者 Huixian Zhu Kangli Shen Ruiqi Liu Chenxin Fang Weiwei Lou Yifan Jiang Wangrui Yuan Xin Cao Liang Chen Qianxing Zhuang 《Neural Regeneration Research》 SCIE CAS CSCD 2025年第6期1628-1643,共16页
The globus pallidus plays a pivotal role in the basal ganglia circuit. Parkinson's disease is characterized by degeneration of dopamine-producing cells in the substantia nigra, which leads to dopamine deficiency i... The globus pallidus plays a pivotal role in the basal ganglia circuit. Parkinson's disease is characterized by degeneration of dopamine-producing cells in the substantia nigra, which leads to dopamine deficiency in the brain that subsequently manifests as various motor and non-motor symptoms. This review aims to summarize the involvement of the globus pallidus in both motor and non-motor manifestations of Parkinson's disease. The firing activities of parvalbumin neurons in the medial globus pallidus, including both the firing rate and pattern, exhibit strong correlations with the bradykinesia and rigidity associated with Parkinson's disease. Increased beta oscillations, which are highly correlated with bradykinesia and rigidity, are regulated by the lateral globus pallidus. Furthermore,bradykinesia and rigidity are strongly linked to the loss of dopaminergic projections within the cortical-basal ganglia-thalamocortical loop. Resting tremors are attributed to the transmission of pathological signals from the basal ganglia through the motor cortex to the cerebellum-ventral intermediate nucleus circuit. The cortico–striato–pallidal loop is responsible for mediating pallidi-associated sleep disorders. Medication and deep brain stimulation are the primary therapeutic strategies addressing the globus pallidus in Parkinson's disease. Medication is the primary treatment for motor symptoms in the early stages of Parkinson's disease, while deep brain stimulation has been clinically proven to be effective in alleviating symptoms in patients with advanced Parkinson's disease,particularly for the movement disorders caused by levodopa. Deep brain stimulation targeting the globus pallidus internus can improve motor function in patients with tremordominant and non-tremor-dominant Parkinson's disease, while deep brain stimulation targeting the globus pallidus externus can alter the temporal pattern of neural activity throughout the basal ganglia–thalamus network. Therefore, the composition of the globus pallidus neurons, the neurotransmitters that act on them, their electrical activity,and the neural circuits they form can guide the search for new multi-target drugs to treat Parkinson's disease in clinical practice. Examining the potential intra-nuclear and neural circuit mechanisms of deep brain stimulation associated with the globus pallidus can facilitate the management of both motor and non-motor symptoms while minimizing the side effects caused by deep brain stimulation. 展开更多
关键词 anxiety basal ganglia bradykinesia deep brain stimulation depression globus pallidus externus globus pallidus internus lateral globus pallidus medial globus pallidus neural circuit Parkinson's disease
暂未订购 下载PDF
芪脊舒僵方治疗僵直少动型帕金森病脾肾阳虚证临床疗效观察 认领 引用 被引量：2
5
作者 刘贝 杨枫 +1 位作者 董英 何建成 《中华中医药杂志》 CAS CSCD 北大核心 2025年第7期3946-3951,共6页
目的:观察芪脊舒僵方治疗僵直少动型帕金森病脾肾阳虚证患者的临床疗效。方法:64例僵直少动型帕金森病脾肾阳虚证患者随机分为对照组和治疗组,每组32例。对照组采用多巴丝肼片口服治疗,治疗组在对照组治疗基础上给予芪脊舒僵方口服,两... 目的:观察芪脊舒僵方治疗僵直少动型帕金森病脾肾阳虚证患者的临床疗效。方法:64例僵直少动型帕金森病脾肾阳虚证患者随机分为对照组和治疗组,每组32例。对照组采用多巴丝肼片口服治疗,治疗组在对照组治疗基础上给予芪脊舒僵方口服,两组均连续治疗12周。治疗12周后评价两组患者临床疗效,治疗前及治疗4、8、12周后评价两组患者帕金森病统一评分量表(UPDRS)评分、改良的霍思-雅尔(H-Y)分级评分、中医证候评分。结果:对照组总有效率为43.75%(14/32),治疗组总有效率为87.50%(28/32),治疗组显著高于对照组(P<0.05)。治疗12周后,治疗组H-Y分级较治疗前显著改善(P<0.01),且优于同期对照组(P<0.01)。治疗组治疗4、8、12周后UPDRSⅠ、UPDRSⅡ及治疗8、12周后UPDRSⅢ评分均显著低于同期对照组(P<0.01)。治疗组治疗后畏寒怕冷、自汗、头晕、肢体麻木、疲乏无力、少气懒言、身体疼痛、腰膝酸软、食量、食冷不适中医证候评分均较治疗前显著改善(P<0.05,P<0.01),且肢体麻木、疲乏无力、少气懒言、腰膝酸软、食量、食冷不适中医证候评分显著优于对照组(P<0.01)。结论:芪脊舒僵方能很好地改善僵直少动型帕金森病脾肾阳虚证患者症状,且安全有效。 展开更多
关键词 帕金森病 僵直少动型 芪脊舒僵方 脾肾阳虚证
暂未订购 下载PDF
Voltage adjustment improves rigidity and tremor in Parkinson's disease patients receiving deep brain stimulation 认领 引用 被引量：1
6
作者 Shao-hua Xu Chao Yang +11 位作者 Wen-biao Xian Jing Gu Jin-long Liu Lu-lu Jiang Jing Ye Yan-mei Liu Qi-yu Guo Yi-fan Zheng Lei Wu Wan-ru Chen Zhong pei Ling Chen 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第2期347-352,共6页
Deep brain stimulation of the subthalamic nucleus is recognized as the most effective treatment for moderate and advanced Parkinson＇s disease. Programming of the stimulation parameters is important for maintaining th... Deep brain stimulation of the subthalamic nucleus is recognized as the most effective treatment for moderate and advanced Parkinson＇s disease. Programming of the stimulation parameters is important for maintaining the efficacy of deep brain stimulation. Voltage is consid- ered to be the most effective programming parameter. The present study is a retrospective analysis of six patients with Parkinson＇s disease （four men and two women, aged 37-65 years）, who underwent bilateral deep brain stimulation of the subthalamic nucleus at the First Affiliated Hospital of Sun Yat-sen University, China, and who subsequently adjusted only the stimulation voltage. We evaluated motor symptom severity using the Unified Parkinson＇s Disease Rating Scale Part III, symptom progression using the Hoehn and Yahr scale, and the levodopa equivalent daily dose, before surgery and 1 and 2 years after surgery. The 2-year follow-up results show that rigidity and tremor improved, and clinical symptoms were reduced, while pulse width was maintained at 60 ps and frequency at 130 Hz. Voltage adjust- ment alone is particularly suitable for patients who cannot tolerate multiparameter program adjustment. Levodopa equivalent daily dose was markedly reduced 1 and 2 years after surgery compared with baseline. Our results confirm that rigidity, tremor and bradykinesia can be best alleviated by voltage adjustment. The trial was registered at ClinicalTrials.gov （identifier： NCT01934881）. 展开更多
关键词 nerve regeneration deep brain stimulation Parkinson＇s disease subthalamic nucleus voltage pulse width frequency tremor rigidity bradykinesia axial symptoms neural regeneration
暂未订购 下载PDF
Epalrestat improves motor symptoms by reducing oxidative stress and inflammation in the reserpine induced mouse model of Parkinson’s disease 认领 引用 被引量：7
7
作者 Md.Mahbubur Rahman Rupali Rani Chakraborti +8 位作者 Md.Abdullah Potol Ariful Haque Abir Ozayra Sharmin Mahabub Alam Md.Fazlur Rahman Khan Rownock Afrin Humayra Jannat Rasiqh Wadud Zaki Farhad Habib 《Animal Models and Experimental Medicine》 CAS CSCD 2020年第1期9-21,共13页
Background:Parkinson's disease(PD)is a progressive neurodegenerative disorder affecting a large number of elderly people worldwide.The current therapies for PD are symptom-based;they do not provide a cure but impr... Background:Parkinson's disease(PD)is a progressive neurodegenerative disorder affecting a large number of elderly people worldwide.The current therapies for PD are symptom-based;they do not provide a cure but improve the quality of life.Muscular dysfunction is the hallmark clinical feature of PD and oxidative stress and inflammation play a critical role in its pathogenesis.Epalrestat is used for the treatment of diabetic neuropathy and is known to improve antioxidative defense mechanisms in the CNS.Therefore,in this study,we investigated the role of Epalrestat in the reserpine induced mouse model of PD.Method:We used Swiss Albino mice for the PD model and tested for akinesia/bradykinesia,muscular rigidity,palpebral ptosis,and tremor,as well as conducting swim and open field tests.Brain samples were used to determine oxidative stress parameters and infiltration of immune cells.Results:Epalrestat treatment significantly improved akinesia and bradykinesia,muscular dysfunctions,tremor level,and gait functions compared to the reserpine group.It also improved the latency in the swim test.Eplarestat significantly reduced lipid peroxidation and NO concentration in different brain tissues and increased the activity of antioxidative enzymes,glutathione,catalase,and superoxide dismutase.Furthermore,Epalrestat reduced neuroinflammation by reducing the number of infiltrating immune cells.Conclusion:Eplarestat improves muscular dysfunction in PD by reducing oxidative stress and inflammation. 展开更多
关键词 bradykinesia Epalrestat glutathione oxidative-stress Parkinson's disease
暂未订购 下载PDF
Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: A clinical rating scale 认领 引用 被引量：1
8
作者 Sergei Mechtcheriakov Ivo W Graziadei +5 位作者 André Kugener Julia Wiedemann Chantal Galbavy Hartmann Hinterhuber Josef Marksteiner Wolfgang Vogel 《World Journal of Gastroenterology》 SCIE CAS 2005年第37期5893-5898,共6页
AIM： To evaluate the feasibility of a new clinical rating scale for a standardized assessment of cirrhosis-associated neuro-psychiatric symptoms. METHODS： Forty patients with liver cirrhosis （LC, with or without lo... AIM： To evaluate the feasibility of a new clinical rating scale for a standardized assessment of cirrhosis-associated neuro-psychiatric symptoms. METHODS： Forty patients with liver cirrhosis （LC, with or without low-grade hepatic encephalopathy） were investigated using a clinical neuro-psychiatric rating scale based on a comprehensive list of neurological, psychomotor, cognitive, affective, behavioral symptoms, and symptoms of disturbed bioregulation. RESULTS： The analysis revealed that the majodty of cirrhotic patients showed, besides characteristic neurological symptoms of hepatic encephalopathy, various psychomotor, affective and bioregulatory symptoms （disturbed sleep and sexual dysfunction）. Patients were impaired in the following subscales： sleep and biorhythm disorder （75.0% of patients）, Parkinsonoid symptoms （25.0%）, affective symptoms （17.5%）, and psychomotor retardation （12.5%）. The increase of total neuro-psychiatric clinical score was significantly associated with the degree of hepatic encephalopathy. CONCLUSION： This study suggests that a substantial number of patients with LC and low-grade hepatic encephalopathy manifest various clinical neuro-psychiatric symptoms. The use of a rating scale, which explores clinical dimensions of hepatic encephalopathy, would improve the management of patients with LC. 展开更多
关键词 Liver cirrhosis Hepatic encephalopathy Neuropsychiatric symptoms Clinical neuro-psychiatric rating Bradykinesia
暂未订购 下载PDF
基于可穿戴设备的帕金森病运动迟缓检测评估方法研究进展 认领 引用 被引量：7
9
作者 何娟娟 姚志明 +2 位作者 李波陈 王建国 杨先军 《中国医疗器械杂志》 2019年第6期432-435,共4页
帕金森病(Parkinson's Disease,PD)是一种多发于中老年人群,以运动障碍为主要临床症状的神经退行性疾病。运动迟缓(Bradykinesia)是帕金森病典型运动障碍症状,基于可穿戴设备的运动迟缓检测评估是实现个体化诊疗和远程医疗的重要支... 帕金森病(Parkinson's Disease,PD)是一种多发于中老年人群,以运动障碍为主要临床症状的神经退行性疾病。运动迟缓(Bradykinesia)是帕金森病典型运动障碍症状,基于可穿戴设备的运动迟缓检测评估是实现个体化诊疗和远程医疗的重要支撑。该文主要针对运动迟缓展开调研,重点阐述了现有的运动迟缓可穿戴设备检测评估技术及数据分析方法,并分析讨论了该领域目前存在的一些问题及未来的研究方向。 展开更多
关键词 帕金森病 运动迟缓 UPDRS量表 可穿戴设备 惯性传感器
暂未订购 下载PDF
帕金森病患者运动迟缓症状的定量评估 认领 引用 被引量：8
10
作者 蒋顶 龚大伟 +4 位作者 罗回春 沈天毓 白启帆 王守岩 章文斌 《临床神经外科杂志》 2018年第2期95-101,共7页
目的验证可穿戴定量评估系统在临床评估帕金森病患者运动迟缓症状的可行性及有效性;探讨运动迟缓定量指标的特征及临床意义。方法帕金森病药物治疗组为符合中国帕金森病诊断标准(2016版)的11例原发性帕金森病患者,健康对照组为15名与帕... 目的验证可穿戴定量评估系统在临床评估帕金森病患者运动迟缓症状的可行性及有效性;探讨运动迟缓定量指标的特征及临床意义。方法帕金森病药物治疗组为符合中国帕金森病诊断标准(2016版)的11例原发性帕金森病患者,健康对照组为15名与帕金森病患者年龄、性别相匹配的健康老年人。帕金森病药物治疗组患者进行美多巴冲击试验,状态分为服药前和服药后。所有患者均采用统一帕金森病评分量表(UPDRS)进行评估。应用可穿戴定量评估系统测量两组被试者的翻腕、抬腿、10 m往返范式动作的运动数据,提取幅度、频率等运动指标分别进行组间比较,并与UPDRSⅢ中子项及子项组合进行相关性分析。结果健康对照组与帕金森病药物治疗组服药前及服药后状态的翻腕幅度、步幅、转身时间比较,差异均有统计学意义(P<0.05~0.01)。帕金森病患者服药前转身时间与UPDRS步态(Ⅲ29)、中轴症状(Ⅲ18、19、27~31)和迟缓+中轴症状(Ⅲ18、19、23~31)评分之间均呈正相关(r=0.824,P=0.002;r=0.779,P=0.005;r=0.673,P=0.023)。结论可穿戴定量评估系统可对帕金森病的运动迟缓症状进行定量测量,对药物治疗帕金森病患者运动迟缓症状的效果进行有效评估;为帕金森病的精准治疗提供新的方法。 展开更多
关键词 帕金森病 运动迟缓 运动功能定量评估 可穿戴定量评估系统
暂未订购 下载PDF
帕金森病嗅觉障碍研究进展 认领 引用 被引量：15
11
作者 肖一峰 吴婧 《中国实用神经疾病杂志》 2020年第16期1466-1472,共7页
帕金森病以静止性震颤、行动迟缓、肌张力增高为主要运动症状,同时伴有嗅觉减退、便秘、认知障碍、RBD、精神症状、焦虑、抑郁、淡漠、自主神经功能障碍等多种非运动症状。嗅觉障碍是帕金森病常见的非运动症状之一,可早于运动症状数年... 帕金森病以静止性震颤、行动迟缓、肌张力增高为主要运动症状,同时伴有嗅觉减退、便秘、认知障碍、RBD、精神症状、焦虑、抑郁、淡漠、自主神经功能障碍等多种非运动症状。嗅觉障碍是帕金森病常见的非运动症状之一,可早于运动症状数年出现。因此,筛查嗅觉障碍可能有助于早期发现并诊断帕金森病。本文就帕金森病嗅觉障碍的病理生理、危险因素、与其他症状的关系、检查方法及治疗等方面的研究进展做一综述。 展开更多
关键词 帕金森病 嗅觉障碍 非运动症状 病理生理 行动迟缓 肌张力增高
暂未订购 下载PDF
Parkinson Kinetic Graph: Are Motor Fluctuations in Parkinson Disease Related with Disease Duration? 认领 引用 被引量：1
12
作者 Esther Berghuis Barbera Van Harten +2 位作者 Mirjam Van Kesteren-Biegstraaten Wijnand Rutgers Nicolaas Verwey 《Advances in Parkinson's Disease》 CAS 2018年第1期1-6,共6页
Introduction: The Parkinson’s KinetiGraph (PKG) is a digital measurement system for motor fluctuations (FS). The aim of this study is to investigate whether FS, measured by the PKG, are associated with disease durati... Introduction: The Parkinson’s KinetiGraph (PKG) is a digital measurement system for motor fluctuations (FS). The aim of this study is to investigate whether FS, measured by the PKG, are associated with disease duration of Parkinson’s Disease (PD) patients. Material and Methods: 172 PD were included. PKG measurements, clinical data and disease duration were collected. Patients were categorized in four disease duration categories (0 - 5 years, 6 - 7 years, 8 - 11 years and ≥12 years). Kruskal-Wallis and Mann-Whitney U tests were used for statistical analysis. Results: The mean age of the patients is 69.2 years (SD ± 8.13). Disease duration varies between 1 and 28 years. Significant difference was found between the four disease categories in FS (p = 0.050);between group 1 - 3, p = 0.005. Conclusions: As expected, FS measured by PKG increase during disease progression in PD. In advanced disease stages, FS stabilise, indicating that PKG is the most useful in early and moderate stages of PD. 展开更多
关键词 Late Stage Parkinson Disease Levodopa Disease Duration Fluctuations Dyskinesia Bradykinesia
暂未订购 下载PDF
帕金森病患者的中枢电生理表现 认领 引用
13
作者 李文娟 乔鸿飞 +2 位作者 傅静 张慧 苑媛媛 《山西医科大学学报》 CAS 2020年第9期995-998,共4页
目的研究帕金森病(Parkinson’s disease,PD)患者大脑皮层的活动状态,以制定个体化治疗方案,并为帕金森病发病机制的研究提供依据。方法招募不同临床表现的PD患者16名,其中静止性震颤者7名,运动迟缓者9名,Hoehn-Yahr分期2-3期,根据统一... 目的研究帕金森病(Parkinson’s disease,PD)患者大脑皮层的活动状态,以制定个体化治疗方案,并为帕金森病发病机制的研究提供依据。方法招募不同临床表现的PD患者16名,其中静止性震颤者7名,运动迟缓者9名,Hoehn-Yahr分期2-3期,根据统一帕金森病评定量表-Ⅲ(unified Parkinson’s disease rating scale-Ⅲ,UPDRS-Ⅲ)中单侧肢体得分结果将每组患者肢体分为症状重侧和症状轻侧,所有患者四肢均行皮层运动阈值(motor threshold,MT)、运动诱发电位(motor evoked potential,MEP)、中枢传导时间(central motor conduction time,CMCT)检测,对比组间各检测值有无明显差异。结果静止性震颤组症状较重侧上肢MT与运动迟缓组比较差异有统计学意义(P0.05)。结论不同临床表现的PD患者皮层MT不同,皮层兴奋性的不同可能是导致PD不同临床表现的原因之一。 展开更多
关键词 帕金森病 中枢电生理 静止性震颤 运动迟缓
暂未订购 下载PDF
肌强直对帕金森病患者运动迟缓评分的影响 认领 引用
14
作者 吴璠 于洋 +3 位作者 梁思泉 朱志中 侯玮佳 巫嘉陵 《医学综述》 CAS 2024年第23期2941-2944,F0003,共4页
目的探讨肌强直对帕金森病患者运动迟缓评分的影响。方法选取2021年5月至2023年6月就诊于天津市环湖医院帕金森及功能障碍评估门诊的帕金森病患者100例,根据世界运动障碍学会统一帕金森病综合评定量表第三部分(MDS UPDRS-Ⅲ)3.3单项评... 目的探讨肌强直对帕金森病患者运动迟缓评分的影响。方法选取2021年5月至2023年6月就诊于天津市环湖医院帕金森及功能障碍评估门诊的帕金森病患者100例,根据世界运动障碍学会统一帕金森病综合评定量表第三部分(MDS UPDRS-Ⅲ)3.3单项评分将患者分为伴肌强直组(MDS UPDRS-Ⅲ3.3≥2分,64例)和不伴肌强直组(MDS UPDRS-Ⅲ3.30.05)。结论伴肌强直的帕金森病患者服用左旋多巴类药物后运动迟缓的速度改善更明显,不伴肌强直组运动幅度和节律改善更明显。明确肌强直与运动迟缓的关系,有利于精准评估帕金森病患者的运动迟缓,制订更有针对性的治疗方案。 展开更多
关键词 帕金森病 运动迟缓 肌强直
暂未订购 下载PDF
微电极导向苍白球腹后部毁损术治疗帕金森病 认领 引用
15
作者 张荣伟 司永兵 +3 位作者 张洪俊 袁绍基 陈世文 武玉良 《前卫医药杂志》 2001年第1期16-17,共2页
目的　探讨苍白球腹后部毁损术 (PVP)治疗帕金森病 (PD)的手术方法及疗效。方法　采用坐标定位结合MRI图象定位 ,在微电极导向下 ,完成对 6例病人单侧苍白球腹后部 (Gpi)的定位 ,并实施毁损。结果　 6例病人的震颤、僵硬及运动迟缓均得... 目的　探讨苍白球腹后部毁损术 (PVP)治疗帕金森病 (PD)的手术方法及疗效。方法　采用坐标定位结合MRI图象定位 ,在微电极导向下 ,完成对 6例病人单侧苍白球腹后部 (Gpi)的定位 ,并实施毁损。结果　 6例病人的震颤、僵硬及运动迟缓均得到明显改善 ,UPDRS运动部分积分“开”状态下改善率 32 .2 % ,“关”状态下改善率 5 8.6 % ,无永久并发症。结论　坐标结合MRI图象法能准确定位Gpi,微电极记录是其必要的补充。PVP能全面改善PD病人的征象 。 展开更多
关键词 帕金森病 苍白球腹后部毁损术 震颤 僵硬 运动迟缓
暂未订购 下载PDF
认知-运动双任务训练对精神发育迟滞伴运动迟缓患儿的疗效分析 认领 引用 被引量：5
16
作者 杨晓春 王东旭 +2 位作者 杨勇 王玮琪 徐礼敬 《中外医学研究》 2022年第10期146-149,共4页
目的:探讨认知-运动双任务训练对精神发育迟滞伴运动迟缓患儿的疗效。方法:选取2018年1月-2021年5月福建中医药大学附属第三人民医院康复科诊治的精神发育迟滞伴运动迟缓患儿100例为研究对象,按照随机数字表法将其分为对照组与观察组,每... 目的:探讨认知-运动双任务训练对精神发育迟滞伴运动迟缓患儿的疗效。方法:选取2018年1月-2021年5月福建中医药大学附属第三人民医院康复科诊治的精神发育迟滞伴运动迟缓患儿100例为研究对象,按照随机数字表法将其分为对照组与观察组,每组50例,其中对照组患儿给予单纯的运动治疗为主的干预方案,观察组患儿在对照组的基础上增加感知信息的输入,给予认知-运动双任务训练,比较两组患儿的康复训练效果。结果:训练前,两组患儿粗大运动商(GMQ)、精细运动商(FMQ)及总运动商(TMQ)评分、智力量表(MDI)与运动量表(PDI)评分、婴儿-初中学生社会生活能力量表(S-M)评分比较,差异均无统计学意义(P>0.05);训练后,观察组患儿的GMQ、FMQ及TMQ评分明显高于对照组,差异均有统计学意义(P<0.05);观察组患儿MDI及PDI评分明显高于对照组,差异均有统计学意义(P<0.05);观察组患儿的S-M评分明显高于对照组,差异均有统计学意义(P<0.05)。结论:对精神发育迟滞伴运动迟缓患儿进行认知-运动双任务训练,可有效提高患儿的智力发育水平,改善肢体协调能力与运动能力,提高社会生活能力。 展开更多
关键词 精神发育迟滞 运动迟缓 认知-运动双任务训练 临床疗效
暂未订购 下载PDF
早期干预降低早产儿脑瘫发生率的观察研究 认领 引用 被引量：3
17
作者 于丽莉 胡恕香 《中国卫生标准管理》 2020年第21期77-80,共4页
目的分析早产儿实施早期干预对降低脑瘫发生率作用。方法选择在本院进行分娩的80例早产儿为研究样本,其研究时间为2017年6月—2019年6月。采取随机数字排列表法将其分成常规组(40例)以及试验组(40例),予以常规组早产儿基础干预措施,采... 目的分析早产儿实施早期干预对降低脑瘫发生率作用。方法选择在本院进行分娩的80例早产儿为研究样本,其研究时间为2017年6月—2019年6月。采取随机数字排列表法将其分成常规组(40例)以及试验组(40例),予以常规组早产儿基础干预措施,采取传统喂养方式以及保健指导,予以试验组早产儿早期干预措施,于早产儿出生后早期对其进行综合干预措施。对比每组早产儿出生6个月时体格发育指标以及脑瘫总发生率。结果试验组早产儿出生6个月时身高、体质量、头围以及胸围长度均高于常规组,两组比较差异有统计学意义(P<0.05);试验组与常规组早产儿脑瘫总发生率分别是2.50%、17.50%,两组比较差异有统计学意义(P<0.05)。结论早产儿实施早期干预措施可降低脑瘫发生率,促进早产儿机体正常生长发育。 展开更多
关键词 发生率 脑瘫 早产儿 早期干预 运动迟缓 神经功能检查
暂未订购 下载PDF
PKG腕表在DBS治疗帕金森病患者运动迟缓症状定量评估中的应用 认领 引用 被引量：1
18
作者 于九江 熊赤 牛朝诗 《立体定向和功能性神经外科杂志》 2020年第1期1-4,共4页
目的探讨(the Parkinson’s KinetiGraph,PKG)腕表定量评估帕金森病(Parkinson’s disease,PD)患者运动迟缓症状的可行性,并分析其随访脑深部刺激术(DBS)治疗后患者运动迟缓症状改变的价值。方法选择2018年2月至2019年1月就诊于安徽医... 目的探讨(the Parkinson’s KinetiGraph,PKG)腕表定量评估帕金森病(Parkinson’s disease,PD)患者运动迟缓症状的可行性,并分析其随访脑深部刺激术(DBS)治疗后患者运动迟缓症状改变的价值。方法选择2018年2月至2019年1月就诊于安徽医科大学附属省立医院并行双侧丘脑底核脑深部刺激术(STN-DBS)治疗PD患者临床资料20例,收集术前、开机1月、开机6月PKG腕表运动迟缓分数((bradykinesia score,BKS)、UPDRS-Ⅲ运动迟缓评分、PDQ-39日常活动评分,分别比较各评分治疗前后差异;将BKS分数和UPDRS-Ⅲ运动迟缓评分分别与PDQ-39日常活动评分做相关性分析并比较差异。结果所有患者手术成功,无死亡或严重并发症发生;治疗前后各评分均存在显著差异,两两比较中,各评分中开机1月和开机6月均显著低于术前(P0.05);BKS评分与PDQ-39日常或评分的相关系数为0.862(P=0.000),高于UPDRS-Ⅲ迟缓评分与PDQ-39日常活动评分的相关系数0.633(P=0.000)。结论PKG腕表BKS分数能有效评估PD患者运动迟缓症状,在随访DBS治疗后患者运动迟缓症状的改变中具有简便易行、省时省力的优点,可在临床上推广。 展开更多
关键词 PKG腕表 帕金森病 脑深部刺激术 运动迟缓 评估
暂未订购 下载PDF
脑深部电刺激未定带在帕金森病治疗中的研究进展 认领 引用
19
作者 李青青 莫诒向 +3 位作者 李梦倩 何骁征 张世忠 侯旭升 《中华神经医学杂志》 CAS CSCD 北大核心 2026年第5期532-537,共6页
帕金森病(PD)负担持续加重是当今老龄化社会面临的重大健康问题之一。脑深部电刺激术(DBS)是PD药物控制效果欠佳后一种有效的外科治疗手段。未定带(ZI)为DBS刺激靶点之一,与皮层、丘脑、基底节、小脑等区域联系紧密。ZI-DBS不仅对PD的... 帕金森病(PD)负担持续加重是当今老龄化社会面临的重大健康问题之一。脑深部电刺激术(DBS)是PD药物控制效果欠佳后一种有效的外科治疗手段。未定带(ZI)为DBS刺激靶点之一,与皮层、丘脑、基底节、小脑等区域联系紧密。ZI-DBS不仅对PD的震颤症状控制效果显著,还对运动迟缓及肌强直有一定的改善效果。本文对ZI-DBS在PD治疗中的研究进展进行综述,以期揭示该脑区在PD治疗中的潜在价值,为相关基础研究和临床转化试验开展提供理论依据与新思路。 展开更多
关键词 帕金森病 未定带 脑深部电刺激术 震颤 运动迟缓 肌强直
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈